












to  good  yields.  Moreover,  the  synthesis  of  multisubstituted  1,4‐
dihydrobenzoxazines‐2‐ones  bearing  a  tetrasubstituted  carbon  atom  is 
described via a one‐pot N‐alkylation/C‐alkylation reactions 
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1,4-Benzoxazines derivatives are an important class of 
heterocyclic compounds present in numerous natural products, 
which have played crucial roles in the area of medicinal 
chemistry over the past decades because of their widespread 
range of biological and pharmaceutical activities.1 Examples of 
dihydrobenzoxazine derivatives with biological activities are the 
compound A with antibacterial propierties2 or the compound B 
that shows hypolipidemia, antiobesity and hypocholesterolemic 
activity.3 A related skeleton is that of 1,4-quinoxaline which also 
exhibits important biological activities.4 So compound C shows 
antiviral activity5 and compound D presents antitumor activity.6 
Consequently, the synthesis of new 1,4-benzoxazine  (and also 
1,4-quinoxaline) derivatives has been and continues to be 
attracting the attention of synthetic organic chemists and 
medicinal chemists. 
 
Figure  1  Biologically  active  dihydrobenzoxazine  and  dihydroquinoxaline 
derivatives 
Traditional methods for building the skeleton of 1,4-
benzoxazines and 1,4-quinoxalines use 2-nitrophenols, 2-
aminophenols or benzene-1,2-diamines as starting materials,7 
although recently several transition-metal catalysed reactions 
have been described.8 Alternatively the modification of 
substituents on the 1,4-benzoxazines have been carried out, 
particularly by the addition of nucleophilic reagents to cyclic 
imines9 (reaction 1, Scheme 1). We envisioned that the 
installation of one additional electron-withdrawing group at C-3 
position as in 2 (Scheme 1) will lead to a highly polarized C=N 
double bond,10,11 that could be considered as an efficient way to 
induce umpolung of the imine functionality.  However, 
considering the system as a whole, it would be an α,β-
unsaturated ester that would undergo conjugate addition at the 
nitrogen atom of the imine functionality. In any case it would be 
a nucleophilic alkylation at the nitrogen atom of the imine group. 
Moreover the intermediate metal enolate obtained in this 
nucleophilic N-alkylation reaction could experience a subsequent 
C-C bond formation by reaction with an alkylating reagent. In the 
literature,12-15 several successfully examples for the 
regioselective N-alkylation of acyclic α-imino esters have been 
described by the groups of Shimizu,13a-d,14a-i Kozlowski,13e-g and 
others.15 However, the N-alkylation of the cyclic α-imino esters 















potential.16,17 Herein, we present our efforts toward the 
nucleophilic N-alkylation of 2-oxobenzoxazine-2-carboxylates 
with organozinc reagents. Furthermore, we report the synthesis 
of multisubstituted 1,4-dihydrobenzoxazin-2-ones bearing a 
quaternary carbon atom by one-pot N-alkylation followed by a C-
alkylation of the enolate produced with alkyl halides. 
 
Scheme 1 Organometallic additions to benzoxazinone derivatives 
Our studies began with the optimization of the reaction 
conditions for the N-alkylation step, using ethyl 2-oxo-2H-
benzo[b][1,4]oxazine-3-carboxylate (2a) as a model substrate 
and Me2Zn as the organozinc reagent. As shown in Table 1, we 
started the optimization process with the screening of various 
solvents (CH2Cl2, toluene and THF, entries 1-3) at room 
temperature, obtaining the best yield of the N-alkylation product 
4aa when CH2Cl2 was used. Next, different temperatures of 
Me2Zn addition reaction were evaluated. The best yield of 
product 4aa (66%) was obtained when Me2Zn was added at 0 °C 
and then the reaction mixture was allowed to reach room 
temperature (entry 4). 
Table 1 Optimization of reaction conditions for the N‐alkylation step.a 
 





1 2 eq. CH2Cl2 rt 60 5 
2 2 eq. toluene rt 45 9 
3 2 eq. THF rt 36 - 
4 2 eq. CH2Cl2 0ºC  to rt 66 10 




Under the best reaction conditions (Table 1, entry 4), the scope 
of the reaction was evaluated using differently substituted ethyl 
2-oxo-benzoxazine-3-carboxylates 2 (Scheme 2). Electron-
donating groups at the 6 or 7 positions of the arene ring of the 
benzoxazine, were well tolerated and the corresponding N-
alkylated products 4ba and 4da were gained with good yields. 
However, when chlorine atoms were installed at position 6 or 7, 
the corresponding products were obtained with lower yields. 
When the reaction was quenched with MeOH, a 
transesterification reaction was observed and the corresponding 
methyl 4-methyl-2-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-3-
carboxylate (4aa’) was obtained in 56% yield. After study of the 
N-alkylation with Me2Zn, we tested the reaction with Et2Zn. The 
corresponding N-alkylation products 4ab, 4cb and 4db, were 
obtained with slightly better yields than when Me2Zn was used as 
organometallic reagent. Very recently, Shimizu has developed the 
N-alkylation of quinoxaline derivatives with Grignard reagents.16 
Therefore, we also decided to examine the addition of dialkylzinc 
reagents to ethyl 3-oxo-3,4-dihydroquinoxaline-2-carboxylate 
derivatives 6 bearing different N-protecting groups such as 
methyl, benzyl or CH2CO2Me. When the reaction was performed 
with Et2Zn,18 the desired N-alkylated products 7ab, 7bb and 7cb	
were obtained with good yields (71-84% yields). 
 
Scheme 2 Scope of the N‐alkylation reaction. 
To increase the synthetic applicability of the N-alkylation of 
benzoxazines and quinoxaline derivatives, we attempted the 
alkylation of the enolates formed after the initial addition of the 
organozinc reagent. In this manner, a tandem N-alkylation/C-
alkylation reaction would be possible for the one-pot three 
component coupling reaction providing dihydrobenzoxazine 
derivatives with a tetrasubstituted carbon atom. For this 
purpose, after the addition of the organozinc reagent, benzyl 
bromide or allyl bromide (5 equivalents) were added to quench 
the reaction mixture. The corresponding enolate generated after 
the addition of Et2Zn was found more reactive than the one 
formed from Me2Zn. The corresponding Et2Zn-enolate was 
trapped with benzyl bromide, affording the corresponding 
product 8b with 51% yield. On the other hand, product 8a, 
obtained from Me2Zn-enolate, was gained with lower yield 
(37%). The corresponding N,C-dialkylated products 8c and 8d, 
with different substitution pattern in the aromatic ring of the 
benzoxazine skeleton, were gained with better yields (67% and 
72%, respectively). Furthermore, we tested allyl bromide as 
electrophile for trapping the enolate. The corresponding allyl 
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substituted products (8e‐8h) were obtained with good yields. 
Our efforts for a tandem N-alkylation/C-alkylation reaction with 
quinoxaline derivatives were unsuccessful, due to the lack of 
reactivity of the corresponding zinc-quinoxaline enolate. Finally, 
when we tested ethyl (E)-4-iodobut-2-enoate as electrophile, 
poor conversion to compound 8i	 was achieved. In order to 
increase the conversion we tried different additives, but all the 
attempts fail. Therefore, the α,β-unsaturated ester 8i with a 
benzoxazine skeleton, was synthesized from the corresponding 
lithium enolate prepared from compound 4ab and LDA in THF, 





In summary, we have developed one-pot synthesis of 
multisubstituted dihydrobenzoxazin-2-ones using a tandem N-
alkylation/C-alkylation process. The reaction proceeds through a 
nucleophilic addition of organozinc reagents to the nitrogen of 
the benzoxazine derivative. The resulting zinc-enolate can be 
trapped with electrophiles to form dihydrobenzoxazin-2-ones 
with a tetrasubstituted carbon atom with moderate to good 
yields. This methodology provides a straightforward procedure 
for the synthesis of a variety of pharmacologically and 
synthetically useful nitrogen heterocycles. 
The experimental section has no title; please leave this line here. 
Reactions were carried out under nitrogen in test tubes or round bottom 
flasks oven-dried overnight at 120 °C. Dicloromethane and toluene were 
distilled from CaH2. THF was distilled from sodium benzophenone ketyl. 
Reactions were monitored by TLC analysis using Merck Silica Gel 60 F-254 
thin layer plates. Flash column chromatography was performed on Merck 
silica gel 60, 0.040-0.063 mm. Melting points were determined in capillary 
tubes. NMR spectra were run at 300 MHz for 1H and at 75 MHz for 13C NMR 
using residual non-deuterated solvent  as internal standard (CHCl3:  7.26 
and 77.0 ppm). Chemical shifts are given in ppm. The carbon type was 
determined by DEPT experiments. High resolution mass spectra (ESI) 
were recorded on a AB SCIEX Triple TOFTM spectrometer equipped with 
an electrospray source with a capillary voltage of 4.5 kV(ESI). Ethyl 2-oxo-
2H-benzo[b][1,4]oxazine-3-carboxylates 2 and ethyl 3-oxo-3,4-
dihydroquinoxaline-2-carboxylates 5 were prepared from the 
corresponding aminophenol or the corresponding benzene-1,2-diamine 
as described in the literature.9i, 19 
Procedure	for	the	nucleophilic	N‐alkylation	of	benzoxazinones	
To a solution of benzoxazinone 2 (0.15 mmol) in dichloromethane (2 mL) 
at 0°C, a 2M Me2Zn solution in toluene /1M Et2Zn solution in hexanes 3	
(0.3 mmol) is added dropwise under nitrogen atmosphere. After addition, 
the reaction is placed at room temperature and is stirred till completion 
(TLC, ±30 minutes). The reaction is quenched with aqueous solution of 
Rochelle salt (5 mL), extracted with dichloromethane (3x15 mL), dried 
over anhydrous magnesium sulfate and concentrated under reduced 
pressure. The resulting product is purified by flash column 
chromatography on silica (hexane:ethyl acetate), obtaining product 4. 
Ethyl	 4‐methyl‐2‐oxo‐3,4‐dihydro‐2H‐benzo[b][1,4]oxazine‐3‐
carboxylate	(4aa) 
Yield: 23.4 mg (66%); brown oil 
IR (neat): 1769, 1683, 1502, 1282, 1200, 1013, 745 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.18 – 7.00 (m, 2H), 6.93 – 6.78 (m, 2H), 4.65 
(s, 1H), 4.13 (q, J = 7.1 Hz, 2H), 3.05 (s, 3H), 1.16 (t, J = 7.1 Hz, 3H). 
13C NMR (75MHz, CDCl3): δ 165.43 (C), 160.55 (C), 141.16 (C), 133.45 (C), 
125.52 (CH), 120.16 (CH), 116.48 (CH), 112.94 (CH), 64.94 (CH), 62.36 
(CH2), 36.43 (CH3), 13.9 (CH3). 
HRMS (ESI+): m/z 236.0918 [M + H]+, C12H14NO4 requires 236.0923. 
Ethyl	 4,6‐dimethyl‐2‐oxo‐3,4‐dihydro‐2H‐benzo[b][1,4]oxazine‐3‐
carboxylate	(4ba)	
Yield: 23.6 mg (63%); green oil. 
IR (neat): 1767, 1682, 1508, 1208, 1016, 750 cm-1. 
1H NMR (300 MHz, CDCl3): δ 6.92 (d, J = 8.1 Hz, 1H), 6.71 – 6.58 (m, 2H), 
4.62 (s, 1H), 4.13 (q, J = 7.1 Hz, 2H), 3.03 (s, 3H), 2.33 (s, 3H), 1.17 (t, J = 
7.1 Hz, 3H). 
13C NMR (75MHz, CDCl3): δ 165.55 (C), 160.63 (C), 139.15 (C), 135.29 (C), 
133.09 (C), 120.58 (CH), 116.11 (CH), 113.52 (CH), 64.95 (CH), 62.30 
(CH2), 36.38 (CH3), 21.29 (CH3), 13.96 (CH3). 
HRMS (ESI+): m/z 250.1076 [M + H]+, C13H16NO4 requires 250.1079. 
Ethyl	 6‐chloro‐4‐methyl‐2‐oxo‐3,4‐dihydro‐2H‐
benzo[b][1,4]oxazine‐3‐carboxylate	(4ca)	
Yield: 22.3 mg (55%); orange oil. 
IR (neat): 1777, 1728, 1500, 1202, 1036, 837, 806 cm-1. 
1H NMR (300 MHz, CDCl3): δ 6.96 (d, J = 8.5 Hz, 1H), 6.84 (dd, J = 8.4, 2.3 
Hz, 1H), 6.80 (d, J = 2.3 Hz, 1H), 4.63 (s, 1H), 4.16 (q, J = 7.1 Hz, 2H), 3.03 
(s, 3H), 1.19 (t, J = 7.1 Hz, 3H). 
13C NMR (75MHz, CDCl3): δ 165.05 (C), 159.70 (C), 139.62 (C), 134.43 (C), 
130.77 (C), 119.82 (CH), 117.37 (CH), 113.11 (CH), 64.54 (CH), 62.65 
(CH2), 36.48 (CH3), 13.99 (CH3). 
HRMS (ESI+): m/z 270.0517 [M + H]+, C12H13ClNO4 requires 270.0533. 
Ethyl	 4,7‐dimethyl‐2‐oxo‐3,4‐dihydro‐2H‐benzo[b][1,4]oxazine‐3‐
carboxylate	(4da)	
Yield: 25.6 mg (68%); brown oil. 
IR (neat): 1755, 1740, 1506, 1213, 1178, 1043, 699 cm-1. 
1H NMR (300 MHz, CDCl3): δ 6.91 (ddd, J = 8.1, 1.8, 0.8 Hz, 1H), 6.86 (dd, J 
= 1.9, 0.7 Hz, 1H), 6.71 (d, J = 8.1 Hz, 1H), 4.61 (s, 1H), 4.13 (q, J = 7.1 Hz, 
2H), 3.02 (s, 3H), 2.28 (s, 3H), 1.16 (t, J = 7.1 Hz, 3H). 
13C NMR (75MHz, CDCl3): δ 165.6 (C), 160.8 (C), 141.0 (C), 131.0 (C), 130.0 
(C), 125.9 (CH), 117.0 (CH), 112.7 (CH), 65.0 (CH3), 62.3 (CH2), 36.4 (CH), 
20.5 (CH3), 14.0 (CH3). 
HRMS (ESI+): m/z 250.1077 [M + H]+, C13H16NO4 requires 250.1079. 
Ethyl	 7‐chloro‐4‐methyl‐2‐oxo‐3,4‐dihydro‐2H‐
benzo[b][1,4]oxazine‐3‐carboxylate	(4ea)	
Yield: 20.7 mg (51%); red oil. 
IR (neat): 1769, 1734, 1500, 1195, 1013, 956, 850, 802, 690 cm-1. 
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1H NMR (300 MHz, CDCl3): δ 7.08 (dt, J = 5.6, 2.2 Hz, 2H), 6.74 (d, J = 8.5 
Hz, 1H), 4.64 (s, 1H), 4.15 (q, J = 7.1 Hz, 2H), 3.03 (s, 3H), 1.18 (t, J = 7.1 Hz, 
3H). 
13C NMR (75MHz, CDCl3): δ 165.09 (C), 159.75 (C), 141.22 (C), 132.29 (C), 
125.36 (C), 124.84 (CH), 116.83 (CH), 113.62 (CH), 64.66 (CH2), 62.59 
(CH), 36.53 (CH3), 13.99 (CH3). 
HRMS (ESI+): m/z 270.0523 [M + H]+, C12H13ClNO4 requires 270.0533. 
Ethyl	 4‐ethyl‐2‐oxo‐3,4‐dihydro‐2H‐benzo[b][1,4]oxazine‐3‐
carboxylate	(4ab)	
Yield: 25.8 mg (69%); brown oil. 
IR (neat): 1770, 1674, 1499, 1266, 1206, 1017, 747 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.10 (ddd, J = 8.4, 7.2, 1.5 Hz, 1H), 7.10 – 7.00 
(m, 1H), 6.93 – 6.81 (m, 2H), 4.77 (s, 1H), 4.11 (q, J = 7.1 Hz, 2H), 3.60 (dq, 
J = 14.2, 7.1 Hz, 1H), 3.29 (dq, J = 14.4, 7.2 Hz, 1H), 1.29 (t, J = 7.2 Hz, 3H), 
1.14 (t, J = 7.1 Hz, 3H). 
13C NMR (75MHz, CDCl3): δ 165.99 (C), 161.00 (C), 141.35 (C), 132.83 (C), 
125.37 (CH), 120.03 (CH), 116.69 (CH), 113.34 (CH), 62.29 (CH), 62.17 
(CH2), 43.39 (CH2), 13.91 (CH3), 12.30 (CH3). 
HRMS (ESI+): m/z 250.1067 [M + H]+, C13H16NO4 requires 250.1079. 
Ethyl	 6‐chloro‐4‐ethyl‐2‐oxo‐3,4‐dihydro‐2H‐benzo[b][1,4]oxazine‐
3‐carboxylate	(4cb)	
Yield: 24.3 mg (57%); red oil. 
IR (neat): 1778, 1734, 1501, 1189, 1131, 1046, 836, 804 cm-1. 
1H NMR (300 MHz, CDCl3): δ 6.97 (dd, J = 8.1, 0.8 Hz, 1H), 6.89 – 6.80 (m, 
2H), 4.77 (s, 1H), 4.15 (q, J = 7.1 Hz, 2H), 3.55 (dq, J = 14.2, 7.1 Hz, 1H), 3.28 
(dq, J = 13.6, 7.3 Hz, 1H), 1.29 (t, J = 7.2 Hz, 3H), 1.18 (t, J = 7.1 Hz, 3H). 
13C NMR (75MHz, CDCl3): δ165.6 (C), 160.2 (C) , 139.8 (C), 133.8 (C), 130.7 
(C), 119.7 (CH), 117.6 (CH), 113.4 (CH), 62.6 (CH2), 61.8 (CH), 43.5 (CH2), 
14.0 (CH3), 12.2 (CH3). 
HRMS (ESI+): m/z 284.0689 [M + H]+, C13H15ClNO4 requires 284.0684. 
Ethyl	4‐ethyl‐7‐methyl‐2‐oxo‐3,4‐dihydro‐2H‐benzo[b][1,4]oxazine‐
3‐carboxylate	(4db)	
Yield: 26.9 mg (68%); red oil. 
IR (neat): 1770, 1679, 1512, 1295, 1199, 1150, 1021, 801 cm-1. 
1H NMR (300 MHz, CDCl3): δ 6.91 (ddd, J = 8.1, 1.8, 0.7 Hz, 1H), 6.87 (d, J = 
1.3 Hz, 1H), 6.77 (d, J = 8.1 Hz, 1H), 4.73 (s, 1H), 4.11 (q, J = 7.1 Hz, 2H), 
3.57 (dq, J = 14.2, 7.1 Hz, 1H), 3.25 (dq, J = 14.4, 7.2 Hz, 1H), 2.28 (s, 3H), 
1.27 (t, J = 7.2 Hz, 4H), 1.15 (t, J = 7.1 Hz, 3H). 
13C NMR (75MHz, CDCl3): δ 166.14 (C), 161.30 (C), 141.31 (C), 130.39 (C), 
130.02 (C), 125.84 (CH), 117.22 (CH), 113.29 (CH), 62.29 (CH2), 62.23 
(CH), 43.45 (CH), 20.47 (CH3), 13.97 (CH3), 12.36 (CH3). 
HRMS (ESI+): m/z 264.1229 [M + H]+, C14H18NO4 requires 264.1236. 
Procedure	for	N‐alkylation/transesterification	of	benzoxazinone	
To a solution of benzoxazinone 2a (0.15 mmol) in dichloromethane (2 
mL) at 0°C, a 2M Me2Zn solution in toluene 3a (0.3 mmol) is added 
dropwise under nitrogen atmosphere. After addition, the reaction is 
placed at room temperature and is stirred for 30 minutes. Dry methanol 
(3 mmol) is added to the reaction and the resulting mixture is stirred till 
completion (TLC, ±30 minutes). The reaction is quenched with Rochelle 
salt (5 mL), extracted with dichloromethane (3x15 mL), dried over 
anhydrous magnesium sulfate and concentrated under reduced pressure. 
The resulting product is purified by flash column chromatography on 
silica (hexane:ethyl acetate), obtaining product 4aa’	
Methyl	 4‐methyl‐2‐oxo‐3,4‐dihydro‐2H‐benzo[b][1,4]oxazine‐3‐
carboxylate	(4aa’)	
Yield: 18.6 mg (56%); brown oil. 
IR (neat): 1773, 1726, 1504, 1215, 1195, 1023, 740 cm-1. 
1H NMR (300 MHz, CDCl3): 7.13 (td, J = 7.7, 1.5 Hz, 1H), 7.05 (dd, J = 8.0, 
1.5 Hz, 1H), 6.97 – 5.88 (m, 2H), 4.69 (s, 1H), 3.69 (s, 3H), 3.05 (s, 3H). 
13C NMR (75MHz, CDCl3): 166.0 (C), 160.3 (C), 141.0 (C), 133.3 (C), 125.6 
(CH), 120.2 (CH), 116.5 (CH), 113.0 (CH), 64.8 (CH), 53.0 (CH3), 36.4 (CH3). 
HRMS (ESI+): 222.0760 [M + H]+, C11H12NO4 requires 222.0766. 
Procedure	for	the	nucleophilic	N‐alkylation	of	quinoxalinones	
To a solution of quinoxalinone 4 (0.15 mmol) in dichloromethane (2 mL) 
at 0 °C, a 1M Et2Zn solution in hexanes 3b	(0.3 mmol) is added dropwise 
under nitrogen atmosphere. After addition, the reaction is placed at room 
temperature and is stirred till completion (TLC, ±30 minutes). The 
reaction is quenched with Rochelle salt (5 mL), extracted with 
dichloromethane (3x15 mL), dried over anhydrous magnesium sulfate 
and concentrated under reduced pressure. The resulting product is 
purified by flash column chromatography on silica (hexane:ethyl acetate), 
obtaining product 7. 
Ethyl	 1‐ethyl‐4‐methyl‐3‐oxo‐1,2,3,4‐tetrahydroquinoxaline‐2‐
carboxylate	(7ab) 
Yield: 27.9 mg (71%); yellow oil. 
IR (neat): 1699, 1390, 1242, 1148, 764, 663 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.12 – 7.01 (m, 1H), 6.96 (dd, J = 8.0, 1.5 Hz, 
1H), 6.90 – 6.79 (m, 2H), 4.67 (s, 1H), 4.09 (qd, J = 7.1, 2.8 Hz, 2H), 3.58 
(dd, J = 13.7, 6.9 Hz, 1H), 3.42 (s, 3H), 3.26 (dd, J = 13.6, 7.2 Hz, 1H), 1.27 
(t, J = 7.2 Hz, 3H), 1.15 (t, J = 7.1 Hz, 3H). 
13C NMR (75MHz, CDCl3): δ 167.89 (C), 162.17 (C), 135.36 (C), 129.24 (C), 
124.06 (CH), 119.24 (CH), 114.90 (CH), 112.54 (CH), 64.40 (CH), 61.65 
(CH2), 43.64 (CH2), 29.47 (CH3), 14.06 (CH3), 12.34 (CH3). 
HRMS (ESI+): m/z 263.1389 [M + H]+, C14H19N2O3 requires 263.1396. 
Ethyl	 4‐benzyl‐1‐ethyl‐3‐oxo‐1,2,3,4‐tetrahydroquinoxaline‐2‐
carboxylate	(7bb)	
Yield: 42.6 mg (84%); clear oil. 
IR (neat): 1727, 1671, 1506, 1405, 1200, 1004, 741, 720, 696 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.60 – 7.14 (m, 5H), 7.01 (ddd, J = 8.2, 7.3, 1.5 
Hz, 1H), 6.84 (dt, J = 8.0, 1.4 Hz, 2H), 6.73 (ddd, J = 8.2, 7.3, 1.3 Hz, 1H), 
5.75 – 5.50 (m, 1H), 4.77 (s, 1H), 4.73 (d, J = 16.2 Hz, 1H), 4.14 (qd, J = 7.1, 
0.8 Hz, 2H), 3.63 (dq, J = 14.1, 7.1 Hz, 1H), 3.35 (dq, J = 13.5, 7.2 Hz, 1H), 
1.31 (t, J = 7.2 Hz, 3H), 1.18 (t, J = 7.1 Hz, 3H). 
13C NMR (75MHz, CDCl3): δ 167.90 (C), 162.30 (C), 136.58 (C), 135.38 (C), 
128.81 (C), 128.69 (CH), 127.14 (CH), 126.25 (CH), 124.14 (CH), 119.39 
(CH), 115.74 (CH), 112.79 (CH), 64.33 (CH), 61.69 (CH2), 46.51 (CH2), 
43.82 (CH2), 14.07 (CH3), 12.46 (CH3). 
HRMS (ESI+): m/z 339.1704 [M + H]+, C20H23N2O3 requires 339.1709. 
Ethyl	 1‐ethyl‐4‐(2‐methoxy‐2‐oxoethyl)‐3‐oxo‐1,2,3,4‐
tetrahydroquinoxaline‐2‐carboxylate	(7cb)	
Yield: 36.1 mg (75%); yellow oil. 
IR (neat): 1733, 1674, 1396, 1289, 1216, 1194, 1012, 744 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.15 – 6.98 (m, 1H), 6.91 – 6.77 (m, 2H), 6.72 
(dd, J = 8.0, 1.3 Hz, 1H), 4.96 (d, J = 17.5 Hz, 1H), 4.71 (s, 1H), 4.45 (d, J = 
17.5 Hz, 1H), 4.11 (qd, J = 7.1, 1.1 Hz, 2H), 3.75 (s, 3H), 3.59 (dt, J = 14.1, 
7.0 Hz, 1H), 3.30 (dq, J = 14.4, 7.2 Hz, 1H), 1.27 (t, J = 7.2 Hz, 3H), 1.15 (t, J 
= 7.1 Hz, 3H). 
13C NMR (75MHz, CDCl3): δ 168.35 (C), 167.36 (C), 162.27 (C), 135.42 (C), 
128.16 (C), 124.40 (CH), 119.41 (CH), 114.39 (CH), 113.09 (CH), 64.12 
(CH), 61.72 (CH2), 52.44 (CH3), 44.01 (CH2), 43.82 (CH2), 13.97 (CH3), 
12.35 (CH3). 
HRMS (ESI+): m/z 321.1450 [M + H]+, C16H21N2O5 requires 321.1451. 
Procedure	for	N‐alkylation/C‐alkylation	of	benzoxazinones	
To a solution of benzoxazinone 2 (0.15 mmol) in dichloromethane (2 mL) 
at 0°C, a 2M Me2Zn solution in toluene /1M Et2Zn solution in hexanes 3	
(0.3 mmol) is added dropwise under nitrogen atmosphere. After addition, 
the reaction is placed at room temperature and is stirred for 30 minutes. 
After 30 minutes, the electrophile (0.75 mmol) is introduced in the 
reaction, which is stirred at room temperature till completion (TLC). The 
reaction is quenched with Rochelle salt (5 mL), extracted with 
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dichloromethane (3x15 mL), dried over anhydrous magnesium sulfate 
and concentrated under reduced pressure. The resulting product is 
purified by flash column chromatography on silica (hexane:ethyl acetate), 
obtaining product 8a‐8h. 
Ethyl	 3‐benzyl‐4‐methyl‐2‐oxo‐3,4‐dihydro‐2H‐
benzo[b][1,4]oxazine‐3‐carboxylate	(8a)	
Yield: 18.1 mg (37%); yellow oil. 
IR (neat): 1757, 1738, 1499, 1272, 1218, 1181, 1018, 742, 698 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.21 – 7.09 (m, 5H), 7.00 (ddd, J = 8.0, 7.5, 1.5 
Hz, 1H), 6.81 (dd, J = 7.9, 1.6 Hz, 1H), 6.74 – 6.59 (m, 2H), 4.32 – 4.13 (m, 
2H), 3.72 (d, J = 15.0 Hz, 1H), 3.50 (d, J = 15.0 Hz, 1H), 2.89 (s, 3H), 1.17 (t, 
J = 7.1 Hz, 3H). 
13C NMR (75MHz, CDCl3): δ 167.43 (C), 163.76 (C), 139.57 (C), 134.09 (C), 
133.01 (C), 130.00 (CH), 128.27 (CH), 127.14 (CH), 125.36 (CH), 119.03 
(CH), 116.03 (CH), 111.94 (CH), 71.79 (C), 62.58 (CH2), 37.73 (CH2), 32.48 
(CH3), 13.96 (CH3). 
HRMS (ESI+): m/z 326.1389 [M + H]+, C19H20NO4 requires 326.1392. 
Ethyl	 3‐benzyl‐4‐ethyl‐2‐oxo‐3,4‐dihydro‐2H‐benzo[b][1,4]oxazine‐
3‐carboxylate	(8b)	
Yield: 26.0 mg (51%); yellow oil. 
IR (neat): 1753, 1736, 1499, 1235, 1203, 1045, 735, 697 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.12-7.08 (m, 5H), 6.98 (ddd, J = 8.1, 7.4, 1.6 
Hz, 1H), 6.79 (dd, J = 8.0, 1.6 Hz, 1H), 6.72 – 6.58 (m, 2H), 4.27 (qd, J = 7.1, 
1.7 Hz, 2H), 3.62 (d, J = 14.8 Hz, 1H), 3.51 – 3.25 (m, 2H), 3.19 – 3.02 (m, 
1H), 1.24 (t, J = 7.1 Hz, 3H), 1.07 (t, J = 7.0 Hz, 3H). 
13C NMR (75MHz, CDCl3): δ 168.2 (C), 164.1 (C), 139.6 (C), 133.9 (C), 131.4 
(CH), 130.3 (C), 128.2 (CH), 127.1 (CH), 125.3 (CH), 118.6 (CH), 116.3 
(CH), 112.1 (CH), 72.3 (C), 62.6 (CH2), 40.8 (CH2), 38.6 (CH2), 13.9 (CH3), 
12.3 (CH3). 
HRMS (ESI+): m/z 340.1548 [M + H]+, C20H22NO4 requires 340.1549. 
Ethyl	 3‐benzyl‐4,6‐dimethyl‐2‐oxo‐3,4‐dihydro‐2H‐
benzo[b][1,4]oxazine‐3‐carboxylate	(8c)	
Yield: 35.5 mg (67%); clear oil. 
IR (neat): 1755, 1740, 1506, 1234, 1213, 1078, 1043, 799, 699 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.41-7.09 (m, 5H), 6.69 (d, J = 8.0 Hz, 1H), 
6.52 – 6.40 (m, 2H), 4.25 (qd, J = 7.2, 1.9 Hz, 2H), 3.63 (d, J = 14.8 Hz, 1H), 
3.43 (d, J = 14.7 Hz, 1H), 3.47 – 3.27 (m, 1H), 3.09 (dq, J = 14.2, 7.1 Hz, 1H), 
1.23 (t, J = 7.1 Hz, 3H), 1.06 (t, J = 7.0 Hz, 3H). 
13C NMR (75MHz, CDCl3): δ 168.3 (C), 164.2 (C), 137.7 (C), 134.9 (C), 134.1 
(C), 131.1 (C), 130.3 (CH), 128.1 (CH), 127.1 (CH), 119.2 (CH), 116.0 (CH), 
112.8 (CH), 72.3 (C), 62.6 (CH2), 40.8 (CH2), 38.5 (CH2), 21.4 (CH3), 13.9 
(CH3), 12.42 (CH3). 
HRMS (ESI+): m/z 354.1709 [M + H]+, C21H24NO4 requires 354.1705. 
Ethyl	 3‐benzyl‐7‐chloro‐4‐methyl‐2‐oxo‐3,4‐dihydro‐2H‐
benzo[b][1,4]oxazine‐3‐carboxylate	(8d)	
Yield: 40.4 mg (72%); yellow oil. 
IR (neat): 1763, 1744, 1497, 1264, 1240, 1042, 1021, 795, 746, 697 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.16 – 7.01 (m, 5H), 6.94 (dd, J = 8.7, 2.4 Hz, 
1H), 6.77 (d, J = 2.4 Hz, 1H), 6.52 (d, J = 8.8 Hz, 1H), 4.28 (qd, J = 7.1, 3.1 
Hz, 2H), 3.61 (d, J = 14.7 Hz, 1H), 3.46 (s, 1H), 3.47 – 3.28 (m, 1H), 3.10 (dq, 
J = 14.3, 7.1 Hz, 1H), 1.25 (t, J = 7.1 Hz, 3H), 1.06 (t, J = 7.0 Hz, 3H). 
13C NMR (75MHz, CDCl3): δ 167.8 (C), 163.6 (C), 139.6 (C), 133.6 (C), 130.3 
(C), 130.2 (CH), 128.3 (CH), 127.3 (CH), 125.0 (CH), 123.0 (C), 116.6 (CH), 
112.7 (CH), 72.2 (C), 62.8 (CH2), 40.9 (CH2), 38.8 (CH2), 13.9 (CH3), 12.1 
(CH3). 
HRMS (ESI+): m/z 374.1165 [M + H]+, C20H21ClNO4 requires 374.1159. 
Ethyl	 3‐allyl‐4‐ethyl‐2‐oxo‐3,4‐dihydro‐2H‐benzo[b][1,4]oxazine‐3‐
carboxylate	(8e)	
Yield: 27.3 mg (63%); brown oil. 
IR (neat): 1762, 1739, 1498, 1271, 1215, 1130, 1020, 744, 660 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.12 – 7.07 (m, 1H), 7.06 – 6.99 (m, 1H), 6.85 
(dd, J = 7.7, 1.6 Hz, 1H), 6.85 – 6.75 (m, 1H), 4.12 (qd, J = 7.1, 1.4 Hz, 1H), 
3.45 (dq, J = 14.4, 7.2 Hz, 2H), 3.28 (dd, J = 14.9, 7.0 Hz, 1H), 3.26 – 3.11 
(m, 1H), 3.00 – 2.85 (m, 1H), 1.20 (t, J = 7.0 Hz, 3H), 1.10 (t, J = 7.1 Hz, 3H). 
13C NMR (75MHz, CDCl3): δ 168.2 (C), 163.6 (C), 140.6 (C), 132.5 (C), 131.1 
(CH), 125.3 (CH), 120.2 (CH2), 119.6 (CH), 116.6 (CH), 113.4 (CH), 70.8 
(C), 62.3 (CH2), 40.1 (CH2), 36.9 (CH2), 13.9 (CH3), 13.0 (CH3). 
HRMS (ESI+): m/z 290.1385 [M + H]+, C16H20NO4 requires 290.1392. 
Ethyl	 3‐allyl‐4‐ethyl‐6‐methyl‐2‐oxo‐3,4‐dihydro‐2H‐
benzo[b][1,4]oxazine‐3‐carboxylate	(8f)	
Yield: 30.5 mg (67%); red oil. 
IR (neat): 1761, 1739, 1506, 1277, 1215, 1180, 1077, 925, 802 cm-1. 
1H NMR (300 MHz, CDCl3): δ 6.89 (d, J = 8.0 Hz, 1H), 6.63 (ddd, J = 8.0, 1.8, 
0.7 Hz, 1H), 6.63 – 6.54 (m, 1H), 5.87 – 5.69 (m, 1H), 5.22 (dq, J = 17.1, 1.6 
Hz, 1H), 5.15 (dq, J = 10.2, 1.4 Hz, 1H), 4.13 (q, J = 7.1 Hz, 2H), 3.43 (dq, J = 
14.4, 7.1 Hz, 1H), 3.34 – 3.22 (m, 1H), 3.17 (ddt, J = 15.1, 6.4, 1.6 Hz, 1H), 
2.90 (ddt, J = 15.1, 7.5, 1.2 Hz, 1H), 2.32 (s, 3H), 1.19 (t, J = 7.0 Hz, 3H), 1.12 
(t, J = 7.1 Hz, 3H). 
13C NMR (75MHz, CDCl3): δ 168.3 (C), 163.6 (C), 138.5 (C), 135.0 (C), 132.1 
(C), 131.2 (CH), 120.1 (CH), 120.1 (CH2), 116.2 (CH), 114.0 (CH), 70.8 (C), 
62.3 (CH2), 40.1 (CH2), 36.9 (CH2), 21.4 (CH3), 13.9 (CH3), 13.0 (CH3). 
HRMS (ESI+): m/z 304.1550 [M + H]+, C17H22NO4 requires 304.1549. 
Ethyl	 3‐allyl‐4‐ethyl‐7‐methyl‐2‐oxo‐3,4‐dihydro‐2H‐
benzo[b][1,4]oxazine‐3‐carboxylate	(8g)	
Yield: 30.9 mg (68%); orange oil. 
IR (neat): 1762, 1738, 1511, 1273, 1229, 1144, 1020, 802 cm-1. 
1H NMR (300 MHz, CDCl3): δ 6.88 (ddd, J = 8.2, 1.9, 0.8 Hz, 1H), 6.84 (dd, J 
= 1.8, 0.8 Hz, 1H), 6.70 (d, J = 8.3 Hz, 1H), 5.90 – 5.70 (m, 1H), 5.22 (dq, J = 
17.1, 1.6 Hz, 1H), 5.16 (dq, J = 10.2, 1.4 Hz, 1H), 4.11 (qd, J = 7.2, 0.9 Hz, 
2H), 3.42 (dq, J = 14.4, 7.2 Hz, 1H), 3.32 – 3.21 (m, 1H), 3.22 – 3.12 (m, 1H), 
2.90 (ddt, J = 15.1, 7.4, 1.2 Hz, 1H), 2.27 (s, 3H), 1.17 (t, J = 7.0 Hz, 3H), 1.10 
(t, J = 7.1 Hz, 3H). 
13C NMR (75MHz, CDCl3): δ 168.3 (C), 163.8 (C), 140.6 (C), 131.3 (CH), 
130.1 (C), 129.6 (C), 125.7 (CH), 120.0 (CH2), 117.1 (CH), 113.5 (CH), 70.8 
(C), 62.2 (CH2), 40.1 (CH2), 36.7 (CH2), 20.4 (CH3), 13.9 (CH3), 13.1(CH3). 
HRMS (ESI+): m/z 304.1550 [M + H]+, C17H22NO4 requires 304.1549.. 
Ethyl	 3‐allyl‐7‐chloro‐4‐ethyl‐2‐oxo‐3,4‐dihydro‐2H‐
benzo[b][1,4]oxazine‐3‐carboxylate	(8h)	
Yield: 24.8 mg (51%); orange oil. 
IR (neat): 1770, 1740, 1494, 1273, 1218, 1147, 1077, 858, 801 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.08 – 7.01 (m, 2H), 6.71 (d, J = 8.5 Hz, 1H), 
5.76 (dddd, J = 16.7, 10.2, 7.5, 6.4 Hz, 1H), 5.29 – 5.13 (m, 2H), 4.13 (q, J = 
7.1 Hz, 2H), 3.43 (dq, J = 14.4, 7.2 Hz, 1H), 3.33 – 3.23 (m, 1H), 3.18 (ddt, J 
= 15.2, 6.4, 1.4 Hz, 1H), 2.92 (ddt, J = 15.1, 7.4, 1.1 Hz, 1H), 1.18 (t, J	= 6.9Hz, 
3H), 1.13 (t, J = 7.2 Hz, 3H). 
13C NMR (75MHz, CDCl3): δ 167.8 (C), 162.9 (C), 140.7 (C), 131.4 (C), 130.8 
(CH), 125.1 (CH), 124.2 (C), 120.5 (CH2), 116.9 (CH), 114.1 (CH), 70.7 (C), 
62.5 (CH2), 40.2 (CH2), 36.9 (CH2), 13.9 (CH3), 12.78 (CH3). 




To a solution of product 4ab (0.1 mmol) in THF (1 mL) at -78 °C, LDA 2M 
in THF (1.2 mmol) is added and the reaction is stirred for half an hour at -
78°C. After half an hour, ethyl (E)-4-iodobut-2-enoate is added at -78 °C 
and is allowed to reach room temperature. The reaction is stirred till 
completion (TLC). The reaction is quenched with saturated aqueous 
solution of ammonium chloride (5 mL), extracted with dichloromethane 
(3x15 mL), dried over anhydrous magnesium sulfate and concentrated 
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under reduced pressure. The resulting product is purified by flash column 
chromatography on silica (hexane:ethyl acetate), obtaining product 8i. 
Yield: 20.1 mg (37%); orange oil. 
IR (neat): 1763, 1730, 1716, 1497, 1263, 1215, 1187, 1130, 1092, 1037, 
746 cm-1. 
1H NMR (300 MHz, CDCl3): δ 7.10 (ddd, J = 8.1, 7.4, 1.6 Hz, 1H), 7.06 – 7.02 
(m, 1H), 6.94 – 6.71 (m, 3H), 5.98 (dt, J = 15.7, 1.5 Hz, 1H), 4.24 – 4.05 (m, 
4H), 3.54 – 3.18 (m, 3H), 3.06 (ddd, J = 15.6, 7.8, 1.4 Hz, 1H), 1.30 – 1.16 
(m, 6H), 1.09 (t, J = 7.1 Hz, 3H). 
13C NMR (75MHz, CDCl3): δ 167.7 (C), 165.6 (C), 163.2 (C), 140.7 (CH), 
140.7 (C), 132.2 (C), 126.0 (CH), 125.5 (CH), 120.1 (CH), 116.7 (CH), 113.7 
(CH), 70.3 (C), 62.6 (CH2), 60.5 (CH2), 40.3 (CH2), 35.0 (CH2), 14.2 (CH3), 
13.8 (CH3), 12.9 (CH3). 
HRMS (ESI+): m/z 362. 1587 [M + H]+, C19H24NO6 requires 362,1598. 
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